Vertex Pharmaceuticals
VRTX
515.02
-5.64
-1.08%
Vertex Pharmaceuticals
US · VRTX
#155 by market cap
Listed 1970
515.02
-5.64
-1.08%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Quant vs Street three independent views, side by side
StockVane factor grade
A-
Momentum strategy signal
Hold
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Improving
4
■ Upgrades■ Downgrades
- 4 upgrades vs 0 downgrades among tracked analyst rating changes.
- Most recent: Maxim Group moved from Hold to Buy on 2026-03-18.
Analyst consensus 21 analysts
Buy
Avg price target 626.06 +21.6%
Price target rangecurrent 515.02
Low563.00
Avg626.06
High725.00
Buy 95%
Hold 5%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-04 | UBS | -- | Buy | 640.00 |
| 2026-11-04 | Maxim Group | -- | Buy | 620.00 |
| 2026-11-04 | H.C. Wainwright | -- | Buy | 641.00 |
| 2026-11-04 | Barclays | -- | Buy | 626.00 |
| 2026-11-03 | TD Cowen | -- | Buy | 575.00 |
| 2026-11-03 | UBS | -- | Buy | 640.00 |
| 2026-11-03 | Maxim Group | -- | Buy | 620.00 |
| 2026-11-03 | Scotiabank | -- | Buy | 660.00 |
| 2026-11-03 | Morgan Stanley | -- | Buy | 660.00 |
| 2026-11-03 | Stifel | -- | Hold | 563.00 |
| 2026-11-03 | BMO Capital | -- | Buy | 620.00 |
| 2026-11-03 | Citi | -- | Buy | 585.00 |
| 2026-11-03 | Goldman Sachs | -- | Buy | 725.00 |
| 2026-11-03 | H.C. Wainwright | -- | Buy | 641.00 |
| 2026-11-03 | J.P. Morgan | -- | Buy | 570.00 |
| 2026-11-02 | Cantor Fitzgerald | -- | Buy | 619.00 |
| 2026-11-02 | Wells Fargo | -- | Buy | 650.00 |
| 2026-11-02 | UBS | -- | Buy | 615.00 |
| 2026-11-02 | BofA Securities | -- | Buy | 667.00 |
| 2026-11-02 | Citi | -- | Buy | 585.00 |
| 2026-11-02 | RBC Capital | -- | Buy | 600.00 |
| 2026-10-27 | Citi | -- | Buy | 585.00 |
| 2026-10-27 | Leerink Partners | -- | Buy | -- |
| 2026-10-26 | TD Cowen | -- | Buy | 550.00 |
| 2026-10-26 | UBS | -- | Buy | 615.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-03-18 | Maxim Group | Hold → Buy | 575.00 |
| 2026-01-22 | RBC Capital | Hold → Buy | 546.00 |
| 2026-01-12 | Bernstein | Hold → Buy | -- |
| 2025-12-03 | Morgan Stanley | Hold → Buy | 516.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-02 | After close | ±5.41% | -4.05% (in line) |
| 2026/Q2 | 2026-08-03 | After close | ±5.68% | +1.70% (in line) |
| 2026/Q1 | 2026-05-04 | After close | ±5.98% | -1.28% (in line) |
| 2025/Q4 | 2026-02-12 | After close | ±8.09% | +5.69% (in line) |
| 2025/Q3 | 2025-11-03 | After close | ±6.88% | -1.02% (in line) |
| 2025/Q2 | 2025-08-04 | After close | ±6.72% | -20.60% (beat) |
| 2025/Q1 | 2025-05-05 | After close | ±4.62% | -10.03% (beat) |
| 2024/Q4 | 2025-02-10 | After close | ±4.80% | -3.14% (in line) |
| 2024/Q3 | 2024-11-04 | After close | ±5.30% | +5.73% (beat) |
| 2024/Q2 | 2024-08-01 | After close | ±5.13% | -2.24% (in line) |
| 2023/Q4 | 2024-02-05 | After close | ±4.66% | -2.98% (in line) |
| 2023/Q3 | 2023-11-06 | After close | ±3.97% | -1.95% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:02:21 · For reference only, not investment advice and not tailored to your situation.
Vertex Pharmaceuticals discussion 0 comments